Oculis Closes Phase III Eye Drop Trial Due to Third-Party Administrative Error https://www.biospace.com/drug-development/oculis-closes-phase-iii-eye-drop-trial-due-to-third-party-administrative-error.....
It seems that it is very likely that the CRO's mistake ruined the clinical trial. OPT also looks very similar, it is also ophthalmology!
- Forums
- ASX - By Stock
- OPT
- opt shareholders deserve a conference call
OPT
opthea limited
Add to My Watchlist
0.00%
!
60.0¢

opt shareholders deserve a conference call, page-24
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
60.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $738.7M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
OPT (ASX) Chart |
Day chart unavailable
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online